{
    "symbol": "HTGM",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 20:36:00",
    "content": "  Before we begin the call today, let me remind you that the company's remarks include forward-looking statements within the meaning of the federal securities laws, including statements regarding our expected revenue build and momentum in 2022, expectations regarding profiling revenue in future periods, our expectation that customers may use our HTP and Holt transcriptome mRNA panel for their studies as a result of the harmonized sample preparation protocol, the importance of the company's HTG transcriptome panel, statements related to the company's HTG Therapeutics and Drug Discovery business, the impacts of recent highs, our planned white paper for a specific drug discovery application, our expectation that HTG may become a disruptive hybrid  drug discovery company, expected improvement in the coming quarters or future growth, business momentum and market opportunities and the expected capabilities of our technology."
}